KYTX
Time to buy KYTX?$8.52
$-0.13 (-1.50%)
2 Days. Real Options Skills.
Join options trader Ben Sturgill as he reveals his most reliable options strategies - live. Seats are limited.
Save your seatTrader's Perspective
KYTX ran from roughly $6.80 in mid May to $9.40 later that month after it initiated a rolling biologics license application submission for miv-cel in stiff person syndrome.
The stock has the potential to go down if it loses $8.00 and fails to reclaim it, which could open a retrace toward $7.00 to $7.50. Any delay in the biologics license application path or another equity raise would likely speed up that move.
If KYTX holds the $8.00 to $8.25 support zone, a move back toward $10 to $11 is on the table as the rolling submission story stays in play. Resistance at $9.40 is the first hurdle.
Analyst Ratings
Kyverna Therapeutics Inc. Earnings
We don't currently have information about Kyverna Therapeutics Inc.'s earnings.